Topics

BIONIK Laboratories Announces Third Quarter Fiscal 2020 Financial Results

07:30 EST 14 Feb 2020 | Businesswire

BIONIK Laboratories Corp. (OTCQB: BNKL) ("BIONIK" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the third quarter of fiscal year 2020, ended December 31, 2019.

Financial information for the third quarter of fiscal 2020:

  • Year to date sales for the nine months ended December 31, 2019 are $1,230,074.
  • Reported sales of $158,005 compared to $930,257 in the prior-year quarter; the decrease from the prior period was primarily due to the delay in receiving a purchase order for six robots received in early January 2020 that the Company expected to receive before December 31, 2019, and the inability by its Chinese JV partner to import robotic devices in China.

Corporate highlights for the third fiscal quarter and recent weeks include:

  • Completed rollout of upgraded version of the InMotion® ARM/HAND robotic device to the market.
  • The Company wrote off in the third fiscal quarter the sale of three InMotion® ARM/HAND robotic devices sold to its Chinese JV, after the Company had to cancel the sale of five InMotion® ARM robotic devices sold to the Chinese JV, due to the inability to import robotic devices to China.
  • Received regulatory approval from the South Korea Food and Drug Ministry for the Company's InMotion® ARM; days later the Company's exclusive distributor in South Korea reported its first sale of the InMotion® ARM to SeoSung Rehabilitation Hospital, opening March 1, 2020.
  • Released a new Graphic User Interface on all new InMotion® robots at the end of 2019.
  • Partnered with Intelliware to meet the data connectivity needs of hospitals and healthcare facilities utilizing sensored technologies by providing seamless connectivity between InMotion® robotic devices and hospital information systems. BIONIK’s new InMotion® Connect platform targets the critical need to link patient centric rehabilitation results to patient management portals and electronic medical records (EMR) to any hospital or rehabilitation facility.
  • Partnered with Propel to accelerate new product development and manufacturing of InMotion® robotic systems and services through enhanced Product Lifecycle Management and Quality Management System solutions.
  • Launched a new fund raising of $3 million in convertible loans (up to $7M) to be converted no later than March 31, 2020.
  • Continued development of an InMotion® Home and next generation platform, which is based on the same clinical concepts, clinical data and rehabilitation protocols as the professional products.

Management Commentary

  • Commenting on the quarter, Eric Dusseux, M.D., BIONIK’s Chief Executive Officer, said, “We are very proud to propose to the market our new ARM/HAND robotic device, now improved with an enhanced Graphic User Interface, which we believe is a significant improvement for patient therapy. We see great market traction to our renewed offering with six ARM/HAND robotic devices ordered in the last few weeks. On another note, we are thrilled to receive approval from the Ministry of Food and Drug Safety for our InMotion® ARM robotic systems. This entry into the South Korean market is significant for our Company as we continue to seek penetration throughout Asia, where the medical robotic technologies market is growing rapidly.”

BIONIK continues to expect to achieve the following milestones during the remainder of fiscal year 2020:

  • The Company, through its partnership with Intelliware, intends to customize InMotion® Connect for its strategic accounts, deploying its connectivity hardware and software and putting in place the process to provide each hospital account a customized InMotion® Connect solution. This support includes customization of the connections, HL7 compatibility if needed, and software to meet the requirements of the hospital systems and their EMR. Through this seamless data collection, BIONIK is conducting real-time analysis to support interpretation of patient outcomes as well as supporting the management of these hospitals and rehabilitation facilities to fast-track the adoption curve for this new technology.

Financial Results

Sales for the quarter ended December 31, 2019 were $158,005, compared with $930,257 for the quarter ended December 31, 2018. The decrease reflects the sale of one InMotion® ARM/HAND robot during the third quarter of fiscal 2020, compared with nine InMotion® ARM robotic devices in the prior-year quarter. Eleven robots have been sold year-to-date compared to 21 over the same period in 2018. In addition, deferred revenue, comprised of training to be provided and extended warranties, increased to $677,752 at December 31, 2019 from $467,778 at March 31, 2019. Extended warranties and training are important and growing parts of the Company’s business.

Gross margin for the quarter ended December 31, 2019 was $14,410 or 0.9%, compared to $479,953 or 51.6% for the quarter ended December 31, 2018. The lower gross margin is due to the Company providing 2 robots at no charge to a customer who was promised an upgrade in 2016.

The Company reported a comprehensive loss for the quarter ended December 31, 2019 of $(2,969,949) or loss per share of $(0.58), and a comprehensive loss of $(8,473,278) or loss per share of $(1.99), for the nine months ended December 31, 2019.

BIONIK had cash and cash equivalents of $1,893,517 as of December 31, 2019, compared to $446,779 as of March 31, 2019. The Company’s working capital at December 31, 2019 was $2,714,130, compared to a working capital of $479,408 as of March 31, 2019. The working capital increase at December 31, 2019 is due to the Company raising $9 million and converting these loans and interest into common shares at September 30, 2019.

About BIONIK Laboratories Corp.

BIONIK Laboratories is a robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home. The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and four products in varying stages of development.

For more information, please visit www.BIONIKlabs.com and connect with us on Twitter, LinkedIn, and Facebook.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward- looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons and other robotic rehabilitation products, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, pipeline of potential sales, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the market and projected market for our existing and planned products and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions, and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control.

Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the inability to meet listing standards to uplist to a national stock exchange, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, the extended lead-time needed to close on sales of products, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.

BIONIK Laboratories Corp.
Condensed Consolidated Interim Balance Sheets
(Amounts expressed in US Dollars)

As at

   

As at

December 31,

   

March 31,

2019

   

2019

 

   

(Audited)

$

   

$

Assets

   

Current

   

Cash and cash equivalents

1,893,517

   

446,779

Accounts receivable, net of allowance for doubtful accounts of $167,500 (March 31, 2019 - $Nil)

298,129

   

1,523,193

Prepaid expenses and other receivables

1,729,834

   

1,355,032

Inventories

1,435,421

   

405,682

Due from related parties

19,394

   

18,585

Total Current Assets

5,376,925

   

3,749,271

Equipment

209,593

   

192,528

Technology and other assets

4,219,779

   

4,427,722

Goodwill

22,308,275

   

22,308,275

Total Assets

32,113,942

   

30,677,796

 

   

 

Liabilities and Shareholders' Equity

   

Current

   

Accounts Payable

724,047

   

1,148,852

Accrued liabilities

1,188,149

   

1,653,233

Convertible Loans

72,217

   

-

Deferred revenue - Contract Liabilities

677,752

   

467,778

Total Current Liabilities

2,662,165

   

3,269,863

Shareholders' Equity

   

Preferred Stock, par value $0.001; Authorized 10,000,000 Special Voting Preferred Stock, par value

   

$0.001; Authorized; Issued and outstanding - 1 (March 31, 2019 – 1)

-

   

-

Common Shares, par value $0.001; Authorized - 500,000,000 (March 31, 2019 – 500,000,000); Issued and outstanding 4,987,245 and 139,589 Exchangeable Shares (March 31, 2019 – 3,661,838 and 196,799 Exchangeable Shares)

5,126

   

3,858

Additional paid in capital

84,235,153

   

73,719,299

Deficit

(54,830,651)

   

(46,357,373)

Accumulated other comprehensive income

42,149

   

42,149

Total Shareholders' Equity

29,451,777

   

27,407,933

Total Liabilities and Shareholders' Equity

32,113,942

   

30,677,796

BIONIK Laboratories Corp.
Condensed Consolidated Interim Statements of Operations and Comprehensive (Loss) For the nine month periods ended December 31, 2019 and 2018
(Amounts expressed in U.S. Dollars)

 

 

 

 

 

 

Three months

Nine months

Three months

Nine months

ended

ended

ended

ended

December 31, 2019

December 31, 2019

December 31, 2018

December 31, 2018

$

$

$

$

Sales

158,005

1,230,074

930,257

1,978,675

Cost of Sales

143,595

562,887

450,304

1,087,540

Gross Margin

14,410

667,187

479,953

891,135

 

 

 

 

 

 

 

Operating expenses

Sales and marketing

480,834

1,649,340

515,439

1,485,423

Research and development

1,021,418

2,724,000

779,283

2,135,075

General and administrative

1,087,431

3,129,063

1,022,024

2,932,980

Share-based compensation expense

447,219

1,373,195

191,634

1,226,374

Amortization

69,314

207,943

69,314

209,682

Depreciation

27,636

78,665

15,969

50,190

Total operating expenses

3,133,852

9,162,206

2,593,663

8,039,724

 

Other (income) expenses

Accretion expense

-

-

316,642

2,421,060

Fair Value Adjustment

-

-

-

(337,923)

(Gain) on mark to market re-evaluation

-

-

-

(2,048,697)

Other income

(107,730)

 

(108,016)

 

-

 

-

Other expense

11,798

197,119

1,520

 

61,652

Foreign exchange

(53,561)

(110,844)

(47,709)

(116,715)

Total other expenses (income)

(149,493)

(21,741)

270,453

(20,623)

Net (loss) and comprehensive (loss) for the period

(2,969,949)

(8,473,278)

(2,384,163)

(7,127,966)

 

Loss per share - basic and diluted

(0.58)

(1.99)

(0.91)

(3.14)

 

Weighted average number of shares outstanding – basic and diluted

5,126,834

4,264,723

2,611,538

2,267,906

BIONIK Laboratories Corp.
Condensed Consolidated Interim Statements of Cash Flows for the nine months periods ended December 31, 2019 and 2018
(Amounts expressed in U.S. Dollars)

 

Nine months ended

Nine months ended

December 31, 2019

December 31, 2018

 

$

$

Operating activities

 

 

Net loss for the period

(8,473,278)

(7,127,966)

Adjustment for items not affecting cash:

 

 

Depreciation

78,665

50,190

Amortization

207,943

209,682

Interest expense

146,144

129,933

Share based compensation expense

1,373,195

1,226,374

Accretion expense

-

2,421,060

Fair value adjustment

-

(337,923)

Gain on mark to market reevaluation

-

(2,048,697)

Allowance for doubtful accounts

167,500

6,001

 

(6,499,831)

(5,471,346)

Changes in non-cash working capital items:

 

 

Accounts receivable

1,057,564

(1,314,380)

Prepaid expenses and other receivables

(374,802)

(1,398,301)

Due from related parties

(809)

908

Inventories

(1,029,739)

(98,163)

Accounts payable

(424,805)

669,779

Accrued liabilities

(465,084)

(429,935)

Customer advances

-

(800)

Deferred revenue

209,974

162,473

Net cash (used in) operating activities

(7,527,532)

(7,879,765)

Investing activities

Acquisition of equipment

(95,730)

(26,071)

Net cash (used in) investing activities

(95,730)

(26,071)

Financing activities

 

 

Proceeds from convertible loans

9,070,000

7,826,633

Repayment of demand notes principal

-

(50,000)

Repayment of demand notes interest

-

(2,975)

Proceeds from short term loan

500,000

-

Repayment of short term loan

(500,000)

-

Net cash provided by financing activities

9,070,000

7,773,658

Net increase (decrease) in cash and cash equivalents for the period

1,446,738

(132,178)

Cash and cash equivalents, beginning of period

446,779

507,311

Cash and cash equivalents, end of period

1,893,517

375,133

 

Matt Bretzius
FischTank Marketing and PR matt@fischtankpr.com

NEXT ARTICLE

More From BioPortfolio on "BIONIK Laboratories Announces Third Quarter Fiscal 2020 Financial Results"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Food
Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...